Podcast: The Future Of R&D Is Self-Driving

In this episode of the In Vivo podcast, visionary University of Toronto researcher Alan Aspuru-Guzik talks about the value of generative AI, automation and quantum computing in drug discovery. 

In Vivo Podcast
• Source: Shutterstock

Alan Aspuru-Guzik has managed, at a young age, to co-found four tech/biotech startups, is professor of chemistry and computer science at the University of Toronto, and sits on the boards of AI-driven biotech, Insilico Medicine. It would be challenging to identify his main project, as he is also chair of Toronto’s Vector Institute for Artificial Intelligence and director of Acceleration Consortium, two projects meant to guide the roll out of artificial intelligence safely and effectively, across a swath of industrial sectors and by a range of global stakeholders.

In this episode of the In Vivo podcast, Alan focuses on the value of generative AI, automation and quantum computing in drug discovery.

Timestamp:

Intro

1:20 - Aspuru-Guzik’s academic and career trajectory

3:40 - Generative AI for molecule creation

6:30 - Intrepid Labs: a self-driving lab that combines automation with machine learning to optimize drug formulation

11:10 - Collaborations with pharma, including work with Insilico Medicine

13:40 - The creative potential of generative AI in drug discovery

16:20 - Quantum computing and pharma

19:30 - Combining quantum power with the self-driving lab

22:00 - Ethics in pharma

26:30 - The future of drug discovery and development

More from Innovation

Antag Therapeutics: Developing Peptide-Based Treatments For Obesity Management

 
• By 

Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.

Podcast: Heranova CMO Advocates For Endometriosis Awareness: “Pain Is Not Normal”

 

Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.

HealthTech Innovation Versus Clinician And System Awareness

 
• By 

Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.

Podcast: Meet Grace, The Clinical Trial AI Agent

 
• By 

In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.

More from In Vivo

HealthTech Innovation Versus Clinician And System Awareness

 
• By 

Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By 

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.